BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 17017977)

  • 1. Type 1 11beta-hydroxysteroid dehydrogenase as universal drug target in metabolic diseases?
    Oppermann U
    Endocr Metab Immune Disord Drug Targets; 2006 Sep; 6(3):259-69. PubMed ID: 17017977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of 11beta-hydroxysteroid dehydrogenase in metabolic disease and therapeutic potential of 11beta-hsd1 inhibitors.
    Saiah E
    Curr Med Chem; 2008; 15(7):642-9. PubMed ID: 18336279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
    Morton NM; Seckl JR
    Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
    Masuzaki H; Flier JS
    Curr Drug Targets Immune Endocr Metabol Disord; 2003 Dec; 3(4):255-62. PubMed ID: 14683456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yeast-based assays for screening 11β-HSD1 inhibitors.
    Vanella R; Callari R; Weston A; Heider H; Schwab MS; Kübler E
    Microb Cell Fact; 2016 Mar; 15():52. PubMed ID: 26980090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Readjusting the glucocorticoid balance: an opportunity for modulators of 11beta-hydroxysteroid dehydrogenase type 1 activity?
    Atanasov AG; Odermatt A
    Endocr Metab Immune Disord Drug Targets; 2007 Jun; 7(2):125-40. PubMed ID: 17584152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning.
    Walker BR
    Proc Nutr Soc; 2007 Feb; 66(1):1-8. PubMed ID: 17343766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
    Wang M
    Handb Exp Pharmacol; 2011; (203):127-46. PubMed ID: 21484570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development.
    Ge R; Huang Y; Liang G; Li X
    Curr Med Chem; 2010; 17(5):412-22. PubMed ID: 20015040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action.
    Stewart PM
    Eur J Endocrinol; 2003 Sep; 149(3):163-8. PubMed ID: 12943516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle.
    Stewart PM; Toogood AA; Tomlinson JW
    Horm Res; 2001; 56 Suppl 1():1-6. PubMed ID: 11786677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cortisol metabolism and the role of 11beta-hydroxysteroid dehydrogenase.
    Tomlinson JW; Stewart PM
    Best Pract Res Clin Endocrinol Metab; 2001 Mar; 15(1):61-78. PubMed ID: 11469811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes.
    Morgan SA; Tomlinson JW
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1067-76. PubMed ID: 20707593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome.
    Schnackenberg CG
    Curr Opin Investig Drugs; 2008 Mar; 9(3):295-300. PubMed ID: 18311666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue.
    Seckl JR; Morton NM; Chapman KE; Walker BR
    Recent Prog Horm Res; 2004; 59():359-93. PubMed ID: 14749510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
    Su X; Vicker N; Trusselle M; Halem H; Culler MD; Potter BV
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):169-73. PubMed ID: 18775471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11beta-hydroxysteroid dehydrogenase type 1) gene.
    Iwasaki Y; Takayasu S; Nishiyama M; Tsugita M; Taguchi T; Asai M; Yoshida M; Kambayashi M; Hashimoto K
    Mol Cell Endocrinol; 2008 Mar; 285(1-2):10-8. PubMed ID: 18313835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 11β-Hydroxysteroid dehydrogenase type 1: potential therapeutic target for metabolic syndrome.
    Joharapurkar A; Dhanesha N; Shah G; Kharul R; Jain M
    Pharmacol Rep; 2012; 64(5):1055-65. PubMed ID: 23238463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, UI-1499.
    Byun SY; Shin YJ; Nam KY; Hong SP; Ahn SK
    Life Sci; 2015 Jan; 120():1-7. PubMed ID: 25447448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action.
    Draper N; Stewart PM
    J Endocrinol; 2005 Aug; 186(2):251-71. PubMed ID: 16079253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.